Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus GnRH agonist with primary radiation therapy in high-risk localized or locally advanced prostate cancer
2015-003007-38Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide arm with Placebo arm (2 arms). Primary endpoint: Metastasis-free survival. Status: unknown.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-003007-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003007-38.